The Brains of Women Present a $1 Trillion Opportunity

(SeaPRwire) –   The brain is the area where the consequences of neglecting women’s health are most apparent and most fixable. Bridging the women’s health gap has the potential to boost the global economy by $1 trillion in additional annual GDP. This number should transform the perspective of every corporate board and government budget office on women’s health.

We have overlooked a significant macroeconomic opportunity in women’s health. The Department of Health and Human Services recently held its first-ever National Conference on Women’s Health. This issue now demands the serious attention and thorough approach it warrants.

Although women have longer lifespans than men, they experience approximately 25% more years in ill health. The repercussions are evident in diminished workforce output, strained household budgets, and the future stability of healthcare systems. Following these costs back to their origin reveals the brain as the focal point, making it the logical starting place for the most effective interventions.

Disrupting this cycle calls for coordinated efforts in three key areas. Organizations that fund research must require data separated by sex and support clinical trials specifically for women with brain diseases. Companies should integrate menopause support and cognitive health resources into their standard employee benefits. Additionally, government officials must acknowledge that women’s brain health is fundamental to workforce productivity and the financial health of healthcare systems.

The justification for each of these actions is compelling.

The Alzheimer’s Burden Falls on Women Twice

Women account for almost two-thirds of all Americans diagnosed with Alzheimer’s. They also represent over 60% of caregivers for those with Alzheimer’s and dementia, frequently during their peak career years. This caregiving is often provided without compensation.

The annual cost of dementia to the United States is around $781 billion, encompassing $232 billion for medical and long-term care and $233 billion for unpaid caregiving. This unpaid labor amounts to 6.8 billion hours of work that is absent from GDP calculations, yet it depletes family finances, hinders professional advancement, and withdraws skilled individuals from the workforce. Families bear about 70% of the total lifetime expense of dementia care.

This dual impact—women being at greater risk of getting the disease and more likely to provide care for others with it—explains why Alzheimer’s acts as a brake on the economy. Its influence extends beyond personal health, affecting family stability, the size of the available labor pool, and the sustainability of public health expenditures.

Consequently, the economic argument for prevention is powerful. According to research from the Cutting Alzheimer’s Risk through Endocrinology initiative, reducing the lifetime risk of Alzheimer’s in women by half could save the U.S. economy $4.56 trillion.

The Productivity Drain We Have Accepted

Alzheimer’s is the most obvious example of a wider trend. Working-age women experience significantly higher incidences of depression, anxiety, and the cognitive and emotional impacts of menopause. In the workplace, these issues manifest as lower involvement, increased absences, and higher staff turnover. Alleviating the global burden of depression could generate up to $230 billion in GDP growth from improved productivity. Mitigating anxiety disorders could contribute an additional $169 billion.

Menopause warrants specific focus. It is a neurological process as much as a reproductive one: the transition is linked to observable changes in brain structure, connectivity, and energy use, which can affect thinking and mood. The U.S. economy loses an estimated $26.6 billion each year due to unmanaged menopause symptoms. Despite this, just 21% of companies provide benefits tailored to menopause. The financial logic for employers is stark: replacing one employee can cost between 40% and 200% of their yearly salary. When brain health is ignored, companies incur costs twice: initially through absenteeism, and subsequently through employee turnover.

Why the Market Hasn’t Fixed This

The lack of investment in women’s brain health stems from a vicious cycle. Historically, men’s health has been the norm in medical research and clinical trials, creating a knowledge deficit for women that investors and funders mistakenly interpret as a financial risk. Insufficient research leads to inadequate funding, which in turn slows advancement. This slow progress then seems to justify the initial reluctance to invest.

A mere 6% of private healthcare investment targets women, with most of it focused on reproductive health, maternity care, and cancer. While these are critical fields, major conditions that disproportionately affect women, such as Alzheimer’s and menopause, continue to be severely underfunded. Focusing on just four underserved therapeutic areas for women in the U.S. could reveal a market potential of over $100 billion by 2030.

The returns from these investments are quantifiable and available. A $1 trillion opportunity does not remain untapped because the market failed to notice it; it persists because the market is not structured to recognize it.

This is a solvable issue if we address it with the same promptness and discipline we would apply to any other high-yield investment.